Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder
2006-005674-47Phase 3Completed
- Sponsor
- Servier
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in generalized anxiety disorder (GAD) (3 arms), sponsored by Servier. Primary endpoint: Time to relapse. Started Aug 2007; status: completed.
02
Drugs
agomelatine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2006-005674-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005674-47.